Mutant HSV-2 Vaccine Us8 Gene Segmentation for Neuronal Spread Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solutions for suppressing Herpes Simplex Virus (HSV) infections are inadequate, particularly in preventing recurrence and transmission, and existing vaccines do not effectively address the virus's ability to reactivate and spread within neuronal tissues.
Innovation Solution
A mutant HSV-2 strain with a single inactivating mutation in the Us8 gene is administered in two doses to impede viral spread and induce an anti-HSV immune response, specifically limiting the expression of the first 123 amino acids of the glycoprotein E and impairing anterograde and retrograde neuronal transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a wild-type HSV vaccine is used, then the virus can replicate and spread to induce immune response, but it can also cause neuronal spread and recurrent infections
Solution Approach 1:
The Us8 gene is segmented into two parts: the first 123 amino acids are expressed to maintain immune response induction, while the remaining portion is deleted to eliminate neuronal spread capability. This segmentation allows the vaccine to retain beneficial immunogenicity while removing harmful neuroinvasiveness.
Solution Approach 2:
The harmful portion of the Us8 gene (amino acids 124-508) is extracted and removed from the virus genome, leaving only the beneficial N-terminal portion (amino acids 1-123) that contributes to immune response without enabling neuronal transport.
2Object-affected harmful factors
If the Us8 gene is completely inactivated, then neuronal spread is impeded, but the immune response may be reduced
Solution Approach 1:
Different regions of the Us8 gene are assigned different functional roles: the N-terminal region (amino acids 1-123) is retained for immune response induction, while the C-terminal region (amino acids 124-508) is deleted to prevent neuronal spread. This local differentiation allows simultaneous achievement of safety and efficacy.
3Object-affected harmful factors
If a replication-defective virus is used, then safety is improved, but the ability to induce strong immune response is reduced
Solution Approach 1:
The harmful full-length Us8 gene is converted into a beneficial truncated version that retains immunogenicity while losing neuroinvasiveness. The deleted C-terminal portion that caused neuronal spread is transformed into a safety feature, while the N-terminal portion continues to stimulate immune response.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.